Cargando…

The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like Breast Cancers and Its Prognostic Significance: Results from a Single-Institution Prospective Cohort Study

Purpose: Neoadjuvant endocrine treatment (NET) has become a useful tool for the downstaging of luminal-like breast cancers in postmenopausal patients. It enables us to increase breast- conserving surgery (BCS) rates, provides an opportunity for us to assess in vivo NET effectiveness, and allows us t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martí, Covadonga, Yébenes, Laura, Oliver, José María, Moreno, Elisa, Frías, Laura, Berjón, Alberto, Loayza, Adolfo, Meléndez, Marcos, Roca, María José, Córdoba, Vicenta, Hardisson, David, Rodríguez, María Ángeles, Sánchez-Méndez, José Ignacio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026529/ https://www.ncbi.nlm.nih.gov/pubmed/35448153 http://dx.doi.org/10.3390/curroncol29040179

Ejemplares similares

Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic
por: Martí, Covadonga, et al.
Publicado: (2020)

The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment
por: Martí, Covadonga, et al.
Publicado: (2021)

Surgical Interest of an Accurate Real-World Prediction of Primary Systemic Therapy Response in HER2 Breast Cancers
por: Sánchez-Méndez, Jose Ignacio, et al.
Publicado: (2023)

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
por: Peláez-García, Alberto, et al.
Publicado: (2017)

High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease
por: Heredia-Soto, Victoria, et al.
Publicado: (2018)

Myoinvasive Pattern as a Prognostic Marker in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma
por: Ruz-Caracuel, Ignacio, et al.
Publicado: (2019)

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping
por: Whitworth, Pat, et al.
Publicado: (2016)

Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma
por: Ruz-Caracuel, Ignacio, et al.
Publicado: (2021)

The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer
por: Rivas, Mauricio, et al.
Publicado: (2019)

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
por: Grote, Isabel, et al.
Publicado: (2021)

Proteomic Analysis of Low-Grade, Early-Stage Endometrial Carcinoma Reveals New Dysregulated Pathways Associated with Cell Death and Cell Signaling
por: López-Janeiro, Álvaro, et al.
Publicado: (2021)

Molecular Mechanism of Secondary Endocrine Resistance in Luminal Breast Cancer
por: Wu, Minhua, et al.
Publicado: (2021)

TET2 directs mammary luminal cell differentiation and endocrine response
por: Kim, Mi Ran, et al.
Publicado: (2020)

Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer: A Comprehensive Review
por: Reinert, Tomás, et al.
Publicado: (2016)

MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer
por: Petrelli, Annalisa, et al.
Publicado: (2020)

Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting
por: Grassadonia, Antonino, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2022)

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
por: Saponaro, Mariarosaria, et al.
Publicado: (2022)

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
por: Green, Andrew R, et al.
Publicado: (2016)

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2020)

Optimal management of luminal breast cancer: how much endocrine therapy is long enough?
por: Munzone, Elisabetta, et al.
Publicado: (2018)

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

Endocrine therapy for the treatment of leptomeningeal carcinomatosis in luminal breast cancer: a comprehensive review
por: Fernandes, Leonor, et al.
Publicado: (2020)

p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer
por: Halim, Freda, et al.
Publicado: (2022)

Protection by glia-conditioned medium in a cell model of Huntington disease
por: Ruiz, Carolina, et al.
Publicado: (2012)

Prognosis Stratification Tools in Early-Stage Endometrial Cancer: Could We Improve Their Accuracy?
por: Ramon-Patino, Jorge Luis, et al.
Publicado: (2022)

Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy
por: Murphy, Brenna M., et al.
Publicado: (2021)

Trehalose Reverses Cell Malfunction in Fibroblasts from Normal and Huntington's Disease Patients Caused by Proteosome Inhibition
por: Fernandez-Estevez, Maria Angeles, et al.
Publicado: (2014)

Striatal Infusion of Glial Conditioned Medium Diminishes Huntingtin Pathology in R6/1 Mice
por: Perucho, Juan, et al.
Publicado: (2013)

Potential Benefits of Neoadjuvant Chemotherapy in Clinically Node-Positive Luminal Subtype(−) Breast Cancer
por: Kim, Hyung Suk, et al.
Publicado: (2019)

Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer
por: Morales Murillo, Serafin, et al.
Publicado: (2021)

Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response
por: Thompson, Kevin J, et al.
Publicado: (2022)

Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer
por: Park, Sungmin, et al.
Publicado: (2017)

Targeted Endocrine Agents should be the Dominant Systemic Therapies Prescribed in Luminal A Breast Cancer
por: Davey, Matthew G, et al.
Publicado: (2023)

Early Imaging and Molecular Changes with Neoadjuvant Bevacizumab in Stage II/III Breast Cancer
por: López-Vega, José Manuel, et al.
Publicado: (2021)

Association of SLC12A1 and GLUR4 Ion Transporters with Neoadjuvant Chemoresistance in Luminal Locally Advanced Breast Cancer
por: Justo-Garrido, Montserrat, et al.
Publicado: (2023)

SARS-CoV-2 infection associated with monoclonal gammopathy. A case report based on the study of minimally invasive ultrasound-guided autopsy
por: González-García, María del Carmen, et al.
Publicado: (2022)

Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy
por: Garufi, Giovanna, et al.
Publicado: (2023)

Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
por: Lerebours, Florence, et al.
Publicado: (2021)

Neoadjuvant Endocrine Therapy (NET) in breast cancer – COVID setting
por: Bardoli, Antonio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_53qrf77p9hlmitglbpi3juinhr